Can-Fite to Attend Bio International Convention 2024 Partnering Meetings

PETACH TIKVA, Israel-- Can-Fite BioPharma, a biotechnology company specializing in developing small molecule drugs for oncological and inflammatory diseases, has announced that its Vice President of Business Development, Dr. Sari Fishman, will participate in 23 partnering meetings at the Bio International Convention 2024. The event is scheduled to be held in San Diego, USA, from June 3 to June 6.

Can-Fite has existing out-licensing and distribution agreements with seven pharmaceutical companies across North America, Europe, and Asia. These partnerships involve upfront and milestone payments. The company’s expanding portfolio of drug indications and its advanced pipeline are garnering increased interest from additional potential partners who will be present at the San Diego conference. Can-Fite’s strategy is to focus on clinical development while partnering with companies that have expertise in pharmaceutical distribution and regulatory approval in specific geographic markets.

The company's pipeline includes two orally bioavailable small molecule drugs. Piclidenoson is in Phase 3 clinical trials for the treatment of Psoriasis. Namodenoson is being evaluated in various stages for multiple indications: Phase 3 for advanced liver cancer, Phase 2a for pancreatic cancer, and Phase 2b for Nonalcoholic Steatohepatitis (NASH).

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development company targeting multi-billion dollar markets in cancer, liver diseases, and inflammatory conditions. The company’s leading drug candidate, Piclidenoson, recently completed a Phase III trial for psoriasis and is set to begin a pivotal Phase III trial. Namodenoson, another lead candidate, is undergoing a Phase IIb trial for steatotic liver disease (SLD) and a Phase III trial for hepatocellular carcinoma (HCC). The company also plans a Phase IIa study for pancreatic cancer.

Namodenoson has received Orphan Drug Designation in both the U.S. and Europe and Fast Track Designation from the U.S. Food and Drug Administration as a secondary treatment for HCC. The drug has demonstrated potential in treating other cancers, including colon, prostate, and melanoma. Additionally, Can-Fite's third drug candidate, CF602, has shown promise in treating erectile dysfunction. Collectively, these drugs have demonstrated excellent safety profiles in clinical studies involving over 1,600 patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!